Significant Agreements and Contracts - Additional Information (Detail) $ in Thousands, shares in Millions			1 Months Ended									6 Months Ended	12 Months Ended
	Nov. 15, 2016 USD ($)	Aug. 15, 2016 USD ($)	Jul. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)	Apr. 30, 2016 USD ($)	Feb. 29, 2016 USD ($)	Aug. 31, 2015 USD ($) Antibody	Apr. 30, 2015 USD ($) shares	Aug. 31, 2014 USD ($)	Jul. 31, 2014 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties and licenses													$ 4,017	$ 0	$ 0
Shares granted value													4,741	6,972	3,940
Fair value of the obligation													48,362	12,000
Pre-clinical research and development expense													45,000	24,013	209
Cost-method investments, aggregate carrying amount													112,008	112,008
Grant revenue recognized as the related costs and expenses incurred													1,033	1,530	488
Proceeds from issuance of common stock, net													$ 107,986	0	71,786
Semnur Pharmaceuticals, Inc. [Member] | Chief Executive Officer and Board of Directors [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Outstanding capital stock percentage													5.50%
Nant Cell [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment period for recognition													10 years
Vested equity received								$ 100,000
Common stock received | shares								10
Cost-method investments, aggregate carrying amount													$ 100,000
Nant Cell [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty rate percent of net sales								5.00%
Nant Cell [Member] | Upfront Payment [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue								$ 10,000
T N K Therapeutics Inc | Virttu Biologics Limited [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock to be issued, value	$ 20,000
Percentage of shares held in escrow	20.00%
T N K Therapeutics Inc | Virttu Biologics Limited [Member] | Common Stock [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate value of common stock issued	$ 5,000
Common stock to be issued, value	20,000
T N K Therapeutics Inc | Minimum [Member] | Virttu Biologics Limited [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from issuance of common stock, net	$ 50,000
Scintilla Pharmaceuticals, Inc [Member] | Semnur Pharmaceuticals, Inc. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments to acquire business		$ 60,000
Cash consideration to equity holders		40,000
Business acquisition, common stock consideration		20,000
Business combination contingent consideration escrow share value		$ 6,000
Business combination additional consideration transferred													$ 140,000
Scintilla Pharmaceuticals, Inc [Member] | Maximum [Member] | Semnur Pharmaceuticals, Inc. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Indemnification Period		12 months
Scintilla Pharmaceuticals, Inc [Member] | Minimum [Member] | Semnur Pharmaceuticals, Inc. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Indemnification Period		6 months
Phase I STTR Grant [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of grant													2 years
Grant revenue recognized as the related costs and expenses incurred													$ 256	302
Amount of grant awards										$ 300
Mabtech Limited [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate purchase price of common stock warrants				$ 20,000
Mabtech Limited [Member] | CHINA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of monoclonal antibodies | Antibody							4
Additional payment for license agreement						$ 10,000
Aggregate purchase price of common stock warrants				$ 20,000
Licensing agreement, additional amounts payable													$ 150,000
Licensing agreement, additional amounts payable, term													3 years
Mabtech Limited [Member] | CHINA [Member] | Acquired in-process research and development expense [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial payment for license agreement							$ 10,000
Additional payment for license agreement												$ 30,000
Les Laboratoires Servier [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable up-front payment			$ 27,400
Upfront payment period for recognition													3 years
Royalties and licenses													$ 3,800
Roger Williams Medical Center [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment period for recognition													5 years
Pre-clinical research and development expense													$ 500
Roger Williams Medical Center [Member] | T N K Therapeutics Inc | Common Class A
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Shares granted value					$ 6,000
Gross proceed from shares issued					20,000
Fair value of the obligation					$ 3,400
TSRI License [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Terminate notice of license													60 days
TSRI License [Member] | General and administrative expenses [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Patent prosecution and maintenance costs													$ 106	123	$ 142
Staph Grant III Award [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of grant													2 years
Grant revenue recognized as the related costs and expenses incurred													$ 699	884
Amount of grant awards											$ 1,000
Myc Grant I Award [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of grant													1 year
Grant revenue recognized as the related costs and expenses incurred													$ 0	139
Amount of grant awards									$ 225
WISP1 Grant I Award [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of grant													1 year
Grant revenue recognized as the related costs and expenses incurred													$ 51	$ 156
Amount of grant awards									$ 225